<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONRC-14005106</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2014-08-06</date_registration>
      <primary_sponsor>The First Affiliated Hospital of Wenzhou Medical University</primary_sponsor>
      <public_title>HIGH DOSE RITUXIMAB IN COMBINATION WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION (BEFORE AND AFTER) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN'S LYMPHOMAS.</public_title>
      <acronym />
      <scientific_title>HIGH DOSE RITUXIMAB IN COMBINATION WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION (BEFORE AND AFTER) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN'S LYMPHOMAS</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2006-01-01</date_enrolment>
      <type_enrolment />
      <target_size>1:20;2:20;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=4469</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>Clinical pre-test</phase>
      <hc_freetext>B cell lymphoma</hc_freetext>
      <i_freetext>1:autologous stem cell transplantation;2:rituximab combined with autologous stem cell transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Shi Yifen</firstname>
        <middlename />
        <lastname />
        <address>The Department of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang street, Ouhai district, Wenzhou, Zhejiang, China</address>
        <city />
        <country1 />
        <zip>325015</zip>
        <telephone>+86 13676772628</telephone>
        <email>shiyifen1999@163.com</email>
        <affiliation>The First Affiliated Hospital of Wenzhou Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Yu Kang</firstname>
        <middlename />
        <lastname />
        <address>The Department of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang street, Ouhai district, Wenzhou, Zhejiang, China</address>
        <city />
        <country1 />
        <zip>325015</zip>
        <telephone>+86 13806681379</telephone>
        <email>yukang62@126.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Eligible patients were age 18 to 65 years and had aggressive CD20 B-cell non-Hodgkin's lymphoma, and had experienced relapse or did not achieve CR with a standard anthracycline-based regimen. Before enrollment, CD20 aggressive B-cell lymphoma was histologically con?rmed in all patients. Eligible patients had a WHO performance status of 0 to 1, sensitive to chemotherapy,normal heart function,renal function and liver function.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Exclusion criteria included:
1. CNS involvement; 
2. history of HIV infection; 
3. post-transplantation lymphoproliferative disorder; 
4. previous organ transplant and pregnancy; 
5. allergic to rituximab; 
6. The patients disagree to join this study; 
7. Any factor that interfere the patient to participate or complete the study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>3 year overall survival rate;3 year disease free survival rate;recovery of the neutrophil and platelet count;Immune Reconstitution;prognosis factor;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The First Affiliated Hospital of Wenzhou Medical University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-07-31</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>